Cancer has become very prevalent in modern day society. Just about everyone has been affected by these deadly disease in some either directly or indirectly. Cancer comes in many forms and manifests in many of the body’s organs such as the lungs, liver, or pancreas. The only good thing about this dangerous situation is the research and medications that have been produced over the past decade and these remarkable drugs are saving lives at a much higher rate than ever before. Seattle Genetics is one of the leading Biotechnology Company that specializes in developing and commercializing Antibody Based Therapies in the world.
These are breakthrough therapies that are far more advanced than the old cancer treatments of Chemotherapy and etc. Antibody Drug Conjugates are the name and eradicating cancer is the game. These innovative therapies have targeting capabilities in action as they’ll directed deliver cell killing agents right into dangerous cancerous cells. Another perk of the treatments is that they spare all non-targeted cells within the body which cuts down on nasty side effects. This is the modern day contemporary way of fighting cancer, but every great company should have great leadership and Seattle Genetics is no exception. Clay Siegall is the current President and CEO of the company. He’s been in the industry for decades and has worked with many prominent cancer research organizations such as Bristol Myers Squib, The National Cancer Institute, as well as The National Institute of Health. The good doctor is well accomplished with a Ph.D in Genetics from George Washington University and a B.S. in Zoology from The University of Maryland. Dr. Clay Siegall has taken the company to another level by entering into multiple strategic licensing of these drugs with Pfizer, GlaxoSmithKlien, Genentech, and AbbVie.
The advanced treatments have sold over $325 Million to date and the ADCs are now being used in over 65 countries worldwide. The future of cancer research is looking much more promising and Dr. Clay Siegall is in firm control of it all.